Double-blind, placebo-controlled, randomized, multicentre phase II/III study to evaluate the efficacy and safety of lisuride, applied subcutaneously by means of a minipump in patients with advanced Parkinson's disease refractory to conventional oral therapy.

Trial Profile

Double-blind, placebo-controlled, randomized, multicentre phase II/III study to evaluate the efficacy and safety of lisuride, applied subcutaneously by means of a minipump in patients with advanced Parkinson's disease refractory to conventional oral therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2012

At a glance

  • Drugs Lisuride (Primary) ; Cabergoline; Dopamine receptor agonists; Pramipexole; Ropinirole
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms CALIPSO
  • Most Recent Events

    • 06 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Jun 2008 Axxonis submitted MAA to EMEA for subcutaneous lisuride infusion for advanced Parkinson's Disease.
    • 06 Dec 2007 Results have been reported in an Axxonis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top